2022-RA-919-ESGO A pilot study of interval cytoreductive surgery and HIPEC for advanced epithelial ovarian cancer in the UK

Katelijn Sap, Omer Aziz, Bridget Decruze, Jurjees Hasan, Sarah O'Dwyer, Brett Winter-Roach
2022 Ovarian cancer   unpublished
difference in PFS was observed between treatment arm in patients without HRD positive tumors (HR, 0.92; 95% CI, 0.59-1.43; P=0.69). The effect of the interaction between olaparib and HRD status on PFS, in the interim study, was similar for the two stratification methods (P=0.20). Conclusion The interim results of SOPHiA DDM Dx HRD Solution evaluation study support the value of lpWGS data for patient stratification, making it suitable for HRD testing in the clinical setting.
doi:10.1136/ijgc-2022-esgo.592 fatcat:mznv22qsybe5jaqoedbhdbuhva